Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
guselkumab
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Guselkumab is a human monoclonal IgG1 lambda antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), inhibiting its interaction with the IL-23 receptor. By blocking IL-23, a cytokine involved in inflammatory and immune responses, guselkumab reduces the release of proinflammatory cytokines and chemokines, thereby decreasing inflammation. It is primarily used for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults. Guselkumab was developed by Janssen Pharmaceuticals and is marketed under the brand name Tremfya[3][5][6][7].
- Brand names
- Tremfya
- Other names
- guselkumab
02
Targets
FCGR1A (High affinity immunoglobulin gamma fc receptor I)IL23A (Interleukin-23 p19 Subunit)IL23R (Interleukin-23 Receptor)
Beyond the preview
Go deeper on guselkumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on guselkumab.